Cite
HARVARD Citation
Cunningham‐Bussel, A. et al. (2022). Predictors of Rheumatic Immune‐Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer. Arthritis & rheumatology. 74 (3), pp. 527-540. [Online].